Rapamycin Improves Brain Blood Flow in Middle‑Aged APOE4 Carriers
Rapamycin Boosts Cerebral Perfusion in APOE4 Carriers
A small study at the University of Missouri found that a low dose of rapamycin increases cerebral blood flow in healthy, middle‑aged people who carry the APOE4 gene. The APOE4 allele is the strongest known genetic risk factor for late‑onset Alzheimer’s disease. Participants were healthy and had no cognitive symptoms at the start of the trial. The study was conducted over a few months in 2024.
Wellness Alert
Emotional Intelligence Linked to Workplace Resilience, New Study Finds
Take Charge of Your Health: Why You Are Your Best Medical Advocate
Anxiety in the practice room: How performance stress shapes student well-being
Stop Believing Everything You Hear: The Hidden Cost of Unverified InformationThe researchers measured blood flow in the brain using non‑invasive imaging before and after the rapamycin treatment. Participants received a daily dose that is far below the levels used for organ transplant patients. After several weeks, scans showed a clear rise in blood flow across several brain regions. This improvement is important because reduced perfusion is a hallmark of early Alzheimer’s pathology. The study also noted that the drug’s effect was stronger in women than in men.
The trial included 30 adults, half of whom were women. All were between 45 and 60 years old. None had diagnosed cognitive impairment. The researchers used a double‑blind design, so neither the participants nor the investigators knew who received rapamycin or placebo. The primary outcome was change in cerebral blood flow measured by arterial spin labeling MRI. Results showed a statistically significant increase in perfusion in the rapamycin group compared with placebo. Female carriers experienced the largest gains, suggesting a sex‑specific response. The investigators speculate that estrogen or other hormonal factors may enhance rapamycin’s vascular effects.
Why Do Women Benefit More?
The study raised questions about sex differences in drug response. A follow‑up analysis examined hormone levels and vascular biomarkers. Findings indicated that women had higher baseline levels of a marker called brain‑derived neurotrophic factor. Rapamycin may amplify this factor, leading to better blood vessel function. The researchers caution that the sample size is small and larger studies are needed to confirm these observations. They also note that rapamycin’s known side effects, such as impaired wound healing, were minimal at the low dose used.
The implications of these results are promising. If rapamycin can safely increase brain perfusion, it might delay or prevent the onset of Alzheimer’s in high‑risk individuals. The drug is already approved for other uses, which could expedite clinical trials focused on neuroprotection. However, the study’s pilot nature means that long‑term safety and efficacy remain uncertain. Future research should include diverse populations and longer follow‑up periods.
Frequently Asked Questions
What is rapamycin and how does it work? Rapamycin is an immunosuppressant that inhibits the mTOR pathway. At low doses, it can improve cellular health and extend lifespan in animal models.
Does rapamycin have side effects? Common side effects include mouth sores, high blood sugar, and reduced wound healing. At the low dose used in this study, side effects were mild and transient.
Can rapamycin replace current Alzheimer’s treatments? No. The drug is not yet approved for Alzheimer’s, and more research is needed to confirm its safety and effectiveness in humans.
More stories:
